

---

## Inhalation Sciences Q4 - Rising revenues and close to break even

Redeye provides an update in relation to ISAB's Q4 2023 report. Revenues during the quarter amounted to SEK5.5m (SEK4.1m), and EBIT came in at SEK-0.7m (SEK-1.1m). Overall, the report came in a bit under our expectations; however, we still argue the quarter has been solid as revenues are rising and the company is close to profitability. Upon yesterday's report, we make some short-term estimate changes, which results in an updated base case of SEK16.5 (17).

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Inhalation Sciences Q4 - Rising revenues and close to break even](#)